194 related articles for article (PubMed ID: 34086287)
1. Synthetic Biology Medicine and Bacteria-Based Cancer Therapeutics.
Lee J; Keates AC; Li CJ
Methods Mol Biol; 2021; 2323():267-280. PubMed ID: 34086287
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo gene silencing by TransKingdom RNAi (tkRNAi).
Xiang S; Keates AC; Fruehauf J; Yang Y; Guo H; Nguyen T; Li CJ
Methods Mol Biol; 2009; 487():147-60. PubMed ID: 19301646
[TBL] [Abstract][Full Text] [Related]
3. Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic Salmonella Typhimurium strain.
Yu B; Yang M; Shi L; Yao Y; Jiang Q; Li X; Tang LH; Zheng BJ; Yuen KY; Smith DK; Song E; Huang JD
Sci Rep; 2012; 2():436. PubMed ID: 22666539
[TBL] [Abstract][Full Text] [Related]
4. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals.
Xiang S; Fruehauf J; Li CJ
Nat Biotechnol; 2006 Jun; 24(6):697-702. PubMed ID: 16699500
[TBL] [Abstract][Full Text] [Related]
5. TransKingdom RNA interference: a bacterial approach to challenges in RNAi therapy and delivery.
Keates AC; Fruehauf J; Xiang S; Li CJ
Biotechnol Genet Eng Rev; 2008; 25():113-27. PubMed ID: 21412352
[TBL] [Abstract][Full Text] [Related]
6. Transkingdom RNA interference (tkRNAi): a novel method to induce therapeutic gene silencing.
Nguyen TA; Fruehauf JH
Methods Mol Biol; 2009; 514():27-34. PubMed ID: 19048211
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic intervention alternatives in cancer, using attenuated live bacterial vectors: Salmonella enterica as a carrier of heterologous molecules].
Hernández-Luna MA; Luria-Pérez R; Huerta-Yépez S
Rev Invest Clin; 2013; 65(1):65-73. PubMed ID: 23745445
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity.
Leventhal DS; Sokolovska A; Li N; Plescia C; Kolodziej SA; Gallant CW; Christmas R; Gao JR; James MJ; Abin-Fuentes A; Momin M; Bergeron C; Fisher A; Miller PF; West KA; Lora JM
Nat Commun; 2020 Jun; 11(1):2739. PubMed ID: 32483165
[TBL] [Abstract][Full Text] [Related]
9. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.
Guo Y; Chen Y; Liu X; Min JJ; Tan W; Zheng JH
Cancer Lett; 2020 Jan; 469():102-110. PubMed ID: 31666180
[TBL] [Abstract][Full Text] [Related]
10. Bacterial delivery of siRNAs: a new approach to solid tumor therapy.
Xu DQ; Zhang L; Kopecko DJ; Gao L; Shao Y; Guo B; Zhao L
Methods Mol Biol; 2009; 487():161-87. PubMed ID: 19301647
[TBL] [Abstract][Full Text] [Related]
11. Tumor-targeting amino acid auxotrophic Salmonella typhimurium.
Hoffman RM
Amino Acids; 2009 Sep; 37(3):509-21. PubMed ID: 19291366
[TBL] [Abstract][Full Text] [Related]
12. A novel balanced-lethal host-vector system based on glmS.
Kim K; Jeong JH; Lim D; Hong Y; Yun M; Min JJ; Kwak SJ; Choy HE
PLoS One; 2013; 8(3):e60511. PubMed ID: 23555984
[TBL] [Abstract][Full Text] [Related]
13. Delivery of therapeutic RNA molecules to cancer cells by bacteria.
Lage H; Fruehauf JH
Ther Deliv; 2011 Apr; 2(4):441-9. PubMed ID: 22826853
[TBL] [Abstract][Full Text] [Related]
14. Treating cancer with infection: a review on bacterial cancer therapy.
Wong S; Slavcev RA
Lett Appl Microbiol; 2015 Aug; 61(2):107-12. PubMed ID: 25963599
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of attenuated S. typhimurium carrying shRNA-expressing vectors as a cancer therapeutic.
Yang N; Zhu X; Chen L; Li S; Ren D
Cancer Biol Ther; 2008 Jan; 7(1):145-51. PubMed ID: 18059172
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models.
Fu W; Chu L; Han X; Liu X; Ren D
J Gene Med; 2008 Jun; 10(6):690-701. PubMed ID: 18338832
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic advantage of genetically engineered Salmonella typhimurium carrying short hairpin RNA against inhibin alpha subunit in cancer treatment.
Yoon W; Yoo Y; Chae YS; Kee SH; Kim BM
Ann Oncol; 2018 Sep; 29(9):2010-2017. PubMed ID: 30016386
[TBL] [Abstract][Full Text] [Related]
18. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo.
Shi XH; Liang ZY; Ren XY; Liu TH
Cancer Gene Ther; 2009 Mar; 16(3):227-36. PubMed ID: 18949011
[TBL] [Abstract][Full Text] [Related]
19. Two-step enhanced cancer immunotherapy with engineered
Zheng JH; Nguyen VH; Jiang SN; Park SH; Tan W; Hong SH; Shin MG; Chung IJ; Hong Y; Bom HS; Choy HE; Lee SE; Rhee JH; Min JJ
Sci Transl Med; 2017 Feb; 9(376):. PubMed ID: 28179508
[TBL] [Abstract][Full Text] [Related]
20. Future of Bacterial Therapy of Cancer.
Hoffman RM
Methods Mol Biol; 2016; 1409():177-84. PubMed ID: 26846811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
